-
Specialties
Patient Rating
4.9 /5( out of 123 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.June 29, 2024SUGAR HOUSE HEALTH CENTERDr. Dood is the consummate professional with a skill set that includes surgical prowess and the ability to meet patients where they are, with dignity and respect. I trust him implicitly with my care.
June 27, 2024SUGAR HOUSE HEALTH CENTERDr. Dood is a great doctor to have on your side. He's caring helpful gentle, and he knows how to tell you different things without being harsh, but not sugar coating it either. He makes you feel safe nd understand what is going on.
June 19, 2024HUNTSMAN CANCER CENTERDr. Dood is very knowledgeable and very kind and compassionate. I don't think I would be alive today without him. He is an amazing surgeon.
June 17, 2024SUGAR HOUSE HEALTH CENTERDr Dood is very knowledgeable and personable.
June 10, 2024SUGAR HOUSE HEALTH CENTERVery caring and genuine
June 07, 2024SUGAR HOUSE HEALTH CENTERI was diagnosed with 3C ovarian cancer. Dr. Dood was the primary surgeon for what turned out to be a six hour surgery with complications. My being alive and well almost a year later is evidence of his extraordinary surgical skills. I am also thankful for his professional and pleasant nature. Dr. Dood is definitely one of the best medical professionals I've met, and I am extremely thankful he is on my Oncology team!
June 05, 2024HUNTSMAN CANCER CENTERDr. Dood is the best. So glad he is my dr. He is extremely caring and kind. He is very knowledgeable and great at explaining things so I understand them. I would highly recommend him!
June 05, 2024HUNTSMAN CANCER CENTERA wonderful Doctor, kind, soft spoken and explained everything so clearly. Looking forward to working with Dr Dood! Best name EVER!
May 30, 2024SUGAR HOUSE HEALTH CENTERDr Dood is the best. He helped me with my stoma reverse and did a great job.
-
Board Certification and Academic Information
Academic Departments Obstetrics & Gynecology -Primary Academic Divisions Gynecological Oncology
Selected Publications
Journal Article
- Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018). Defining Survivorship Trajectories Across Patients with Solid Tumors: An Evidence-Based Approach. JAMA Oncol, 4(11), 1519-1526. (Read full article)
- Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer, 28(8), 1485-1490. (Read full article)
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2018). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11). (Read full article)
- Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK (2017). Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther, 17(2), 464-473. (Read full article)
- Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 8(57), 96496-96505. (Read full article)
- Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun, 8(1), 310. (Read full article)
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2(16). (Read full article)
- Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res, 77(11), 2903-2913. (Read full article)
- Dood RL, Gracia CR, Sammel MD, Haynes K, Senapati S, Strom BL (2014). Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol, 21(5), 744-52. (Read full article)
Letter
- Dood RL (2014). Reply: To PMID 24590007. [Letter to the editor]. J Minim Invasive Gynecol, 22(3), 510. (Read full article)